783P Impact of Cemiplimab on Quality of Life (qol), Functioning and Symptoms in Patients (pts) with Recurrent/metastatic (R/M) Cervical Carcinoma: Results from EMPOWER-Cervical 1/Gog-3016/Engot-cx9

A. Oaknin,B. J. Monk,I. Vergote,A. C. de Melo,Y. M. Kim,A. Lisyanskaya,V. Samouelian,H. S. Kim,E. A. Gotovkin,F. Damian,C-L. Chang,S. Takahashi, J. Li,M. Mathias,M. G. Fury,C. Ivanescu,M. Reaney,J. Harnett,C-I. Chen,K. S. Tewari

ANNALS OF ONCOLOGY（2021）

引用 1|浏览14

暂无评分

摘要

Cemiplimab significantly improved overall survival in pts with R/M cervical cancer after first-line (1L) platinum-based chemotherapy (chemo) (NCT03257267; ESMO-VP-2021). We now report patient-reported QoL, functioning and symptoms from the trial.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要